Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemsidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT07284758Phase 2Recruiting
- Sponsor
- C4 Therapeutics
- Start
- Feb 2026
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of cemsidomide in multiple myeloma (MM), sponsored by C4 Therapeutics. Started Feb 2026; status: recruiting.
02
Drugs
cemsidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07284758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284758.